{
    "clinical_study": {
        "@rank": "20198", 
        "arm_group": [
            {
                "arm_group_label": "Mitochondrial Disease", 
                "description": "Individuals with genetic diagnoses (nuclear or mitochondrial) of mitochondrial disease"
            }, 
            {
                "arm_group_label": "Unaffected", 
                "description": "Healthy individuals, without mitochondrial disease"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to use a new research imaging technique, a kind of magnetic\n      resonance imaging (MRI), to measure important metabolic features of muscle, including\n      mitochondrial function, in people with mitochondrial disease and in healthy individuals.\n      (Mitochondria are tiny organelles that generate energy for the body.)\n\n      It is hoped that this new strategy will help physicians to understand better the health\n      problems of people with mitochondrial disease. Eventually, this could lead to better\n      diagnostic and treatment approaches."
        }, 
        "brief_title": "Magnetic Resonance Imaging (MRI) Muscle Phenotyping in Mitochondrial Disease", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Mitochondrial Disease", 
        "condition_browse": {
            "mesh_term": "Mitochondrial Diseases"
        }, 
        "detailed_description": {
            "textblock": "There are two study-related visits.\n\n      The first visit is a \"screening\" visit to ensure eligibility. This includes fasting blood\n      tests. The second visit is an MRI scanning session. This also takes around 2 - 3 hours, with\n      no more than 1.5 hours spent in the actual MRI machine. It may be possible to complete these\n      two visits on the same day. Otherwise, the MRI session should occur within 3 months of the\n      screening visit."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Group 1) Mitochondrial Disease:\n\n        Inclusion Criteria:\n\n          -  Genetic diagnosis of mitochondrial disease\n\n          -  Be able to perform sub-maximal leg exercise for several minutes\n\n          -  Be able to provide written, informed consent\n\n          -  Cognitively and medically stable and able to comply with study procedures\n\n          -  Able to fast for 4 hours prior to blood draw and/or MRI scanning\n\n          -  Be willing to stop taking any over-the-counter vitamins and supplements that are\n             neither prescribed nor recommend by their physician for 2 weeks prior to MRI scanning\n\n        Exclusion Criteria:\n\n          -  Diabetes\n\n          -  Alcohol/substance abuse\n\n          -  Smoking\n\n          -  Use of any investigational agents within 4 weeks of enrollment\n\n          -  Any contraindication to MRI scanning\n\n        Group 2) Healthy Individuals:\n\n        Inclusion Criteria:\n\n          -  Be able to perform sub-maximal leg exercise for several minutes\n\n          -  Be able to provide written, informed consent\n\n          -  Cognitively and medically stable and able to comply with study procedures\n\n          -  Able to fast for 4 hours prior to blood draw and/or MRI scanning\n\n          -  Be willing to stop taking any over-the-counter vitamins and supplements that are\n             neither prescribed nor recommend by their physician for 2 weeks prior to MRI scanning\n\n        Exclusion Criteria:\n\n          -  Carry a diagnosis of mitochondrial disease\n\n          -  Have a first-degree relative with a diagnosis of mitochondrial disease\n\n          -  Diabetes\n\n          -  Alcohol/substance abuse\n\n          -  Smoking\n\n          -  Use of any investigational agents within 4 weeks of enrollment\n\n          -  Any contraindication to MRI scanning"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Two groups of subjects: 1) mitochondrial disease and 2) healthy individuals"
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02154711", 
            "org_study_id": "819440"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "mitochondrial disease", 
            "magnetic resonance imaging", 
            "magnetic resonance spectroscopy", 
            "creatine", 
            "phosphocreatine"
        ], 
        "lastchanged_date": "May 31, 2014", 
        "location": {
            "contact": {
                "email": "mccormacks1@email.chop.edu", 
                "last_name": "Shana E McCormack, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19004"
                }, 
                "name": "University of Pennsylvania"
            }, 
            "investigator": {
                "last_name": "Shana E McCormack, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Magnetic Resonance Imaging (MRI) Muscle Phenotyping in Mitochondrial Disease", 
        "overall_contact": {
            "email": "mccormacks1@email.chop.edu", 
            "last_name": "Shana E McCormack, MD"
        }, 
        "overall_official": {
            "affiliation": "University of Pennsylvania", 
            "last_name": "Shana E McCormack, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Creatine Recovery Time", 
            "safety_issue": "No", 
            "time_frame": "15 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02154711"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Pennsylvania", 
            "investigator_full_name": "Shana McCormack", 
            "investigator_title": "Instructor in Pediatrics", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Phosphocreatine recovery time", 
            "safety_issue": "No", 
            "time_frame": "15 minutes"
        }, 
        "source": "University of Pennsylvania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Observational Model: Case Control, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}